Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen

Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen

Hugues de The and colleagues report thatTP53 status is a predictive factor for responsiveness in breast cancers to a dose-dense epirubicin-cyclophosphamide chemotherapy regimen, and suggests that this regimen might be well suited for patientsTP53 mutant tumors.

Bibliographic Details
Main Authors: Bertheau, Philippe, Turpin, Elisabeth, Rickman, David S, Espié, Marc, de Reyniès, Aurélien, Feugeas, Jean-Paul, Plassa, Louis-François, Soliman, Hany, Varna, Mariana, de Roquancourt, Anne, Lehmann-Che, Jacqueline, Beuzard, Yves, Marty, Michel, Misset, Jean-Louis, Janin, Anne, de Thé, Hugues
Format: Online
Language:English
Published: Public Library of Science 2007
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1831731/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1831731/

Similar Items